Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab steroid-sparing study in severe refractory asthma
NL-OMON37249Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Oct 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma and eosinophilic asthma (EA) comparing Mepolizumab adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: Percent reduction of oral corticosteroid dose at week 24 compared with baseline. Started Oct 2012; status: active, not recruiting.
02
Drugs
mepolizumab
03
Conditions
asthmaeosinophilic asthma (EA)
Beyond the preview
Go deeper on NL-OMON37249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37249.